Pharmosa Biopharm Inc. (TPEX: 6875)
63.40
-3.10 (-4.66%)
Sep 10, 2024, 1:30 PM CST
Pharmosa Biopharm Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 1,750 | 974.06 | 672.51 | 461.46 | 414.54 |
Cash & Short-Term Investments | 1,750 | 974.06 | 672.51 | 461.46 | 414.54 |
Cash Growth | 218.12% | 44.84% | 45.74% | 11.32% | - |
Other Receivables | 6.07 | 1.47 | 0.29 | 0.31 | 0.15 |
Receivables | 6.07 | 1.47 | 0.29 | 0.31 | 0.15 |
Inventory | 36.04 | 21.91 | - | - | - |
Prepaid Expenses | 23.45 | 12.67 | 11.65 | 14.18 | 8.69 |
Other Current Assets | - | - | - | 0.02 | 4 |
Total Current Assets | 1,815 | 1,010 | 684.45 | 475.96 | 427.37 |
Property, Plant & Equipment | 235.77 | 180.61 | 30.12 | 33.44 | 40.86 |
Long-Term Investments | 73.02 | 71.22 | 65.69 | 61.6 | 60.91 |
Other Intangible Assets | 0.1 | 0.09 | 0.15 | 0.18 | - |
Other Long-Term Assets | 92.75 | 71.62 | 18.95 | 15.19 | 14.13 |
Total Assets | 2,217 | 1,334 | 799.37 | 586.37 | 543.27 |
Accounts Payable | 0.36 | 0.59 | - | - | - |
Accrued Expenses | 27.4 | 33.24 | 12.28 | 11.66 | 10.43 |
Short-Term Debt | - | - | - | - | 61 |
Current Portion of Long-Term Debt | - | 1.26 | 3.52 | 8.43 | 18.81 |
Current Portion of Leases | 17.68 | 24.69 | 7.19 | 6.8 | 6.43 |
Other Current Liabilities | 37.45 | 17.8 | 4.77 | 6.19 | 2.58 |
Total Current Liabilities | 111.45 | 77.58 | 27.77 | 33.07 | 99.25 |
Long-Term Debt | - | 1.19 | 2.45 | 5.96 | 14.83 |
Long-Term Leases | 108.69 | 117.23 | 8.04 | 15.9 | 23.36 |
Total Liabilities | 225.1 | 195.99 | 38.25 | 54.93 | 137.44 |
Common Stock | 645.09 | 586.02 | 554.67 | 489.24 | 402.5 |
Additional Paid-In Capital | 1,438 | 531.34 | 1,180 | - | 454.19 |
Retained Earnings | -91.25 | 20.28 | -973.44 | -706.94 | -450.46 |
Comprensive Income & Other | 0.01 | 0.01 | 0.01 | 749.13 | -0.41 |
Shareholders' Equity | 1,992 | 1,138 | 761.12 | 531.44 | 405.83 |
Total Liabilities & Equity | 2,217 | 1,334 | 799.37 | 586.37 | 543.27 |
Total Debt | 126.37 | 144.37 | 21.19 | 37.09 | 124.43 |
Net Cash (Debt) | 1,623 | 829.69 | 651.32 | 424.37 | 290.1 |
Net Cash Growth | 246.74% | 27.39% | 53.48% | 46.28% | - |
Net Cash Per Share | 13.55 | 7.32 | 6.61 | 5.00 | 6.09 |
Filing Date Shares Outstanding | 129.02 | 117.2 | 110.93 | 97.85 | 49.99 |
Total Common Shares Outstanding | 129.02 | 117.2 | 110.93 | 97.85 | 49.99 |
Working Capital | 1,704 | 932.53 | 656.68 | 442.89 | 328.12 |
Book Value Per Share | 15.44 | 9.71 | 6.86 | 5.43 | 8.12 |
Tangible Book Value | 1,992 | 1,138 | 760.97 | 531.25 | 405.83 |
Tangible Book Value Per Share | 15.44 | 9.71 | 6.86 | 5.43 | 8.12 |
Machinery | 55.52 | 27.11 | 26.37 | 17.05 | 19.59 |
Construction In Progress | 49.52 | 35.61 | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.